<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02828137</url>
  </required_header>
  <id_info>
    <org_study_id>INHAUH 2016-06-012</org_study_id>
    <nct_id>NCT02828137</nct_id>
  </id_info>
  <brief_title>Relation Between NLR and IMR in STEMI Patients</brief_title>
  <official_title>Relationships Between Neutrophil-to-Lymphocyte Ratio and Index of Microcirculatory Resistance in ST-segment Elevation Myocardial Infarction Patients Undergone Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inha University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The neutrophil-to-lymphocyte ratio (NLR) has been proven to be reliable inflammatory marker
      for atherosclerotic process and predictor for clinical outcomes in patients with various
      cardiovascular diseases. Recent study reported elevated NLR was associated with impaired
      myocardial perfusion in ST-segment elevation myocardial infarction (STEMI) patients. The
      investigators sought to determine whether NLR is associated with coronary microcirculation
      assessed by index of microcirculatory resistance (IMR) in STEMI patients who undergone
      primary percutaneous coronary intervention (PCI). A total of 123 patients with STEMI
      underwent successful primary PCI were consecutively enrolled. NLR at admission was
      calculated, and the patients were divided into three groups according to NLR tertiles. IMR
      was measured by intracoronary thermodilution-derived method immediately after index PCI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 123 consecutive STEMI patients who underwent successful primary PCI and coronary
      physiologic study immediately after PCI were retrospectively enrolled in the study. All
      patients underwent index PCI between May 2009 and October 2014 at INHA university hospital.
      The definition of STEMI was determined by the current guidelines.

      Complete blood counts, including total and differential WBC counts, were obtained at the time
      of admission. Total counts of WBC, neutrophils, and lymphocytes were assessed using an
      automated blood cell counter (XE-2100, Sysmex Inc., Japan). NLR was calculated as the ratio
      of the neutrophil counts to the lymphocyte counts. All patients were divided into 3 groups
      according to the NLR tertiles.

      The IMR was assessed shortly after primary PCI by using thermodilution-derived method. After
      successful interventional reperfusion, intracoronary nitroglycerin (100~200μg) was
      administered and coronary pressure guidewire (Radi Pressure Wire 5, Radi Medical Systems,
      Uppsala, Sweden) was calibrated outside the patient. The guidewire was equalized at the
      distal tip of guiding catheter, and then advanced towards the distal third of infarct related
      artery (IRA). Three times of saline injection (3~5 ml) were administered to IRA and baseline
      mean transit time was assessed. Microcirculatory hyperemia was induced by using an adenosine
      infusion (140 μg/kg.min) administered via peripheral venous line. During maximal hyperemia,
      hyperemic mean transit time (Tmn) was measured using same method as prior separate saline
      injections. Mean aortic (Pa) and distal coronary pressures (Pd) was measured during
      hyperemia. The IMR was calculated the formula as follows: IMR = Pd x hyperemic Tmn.
      Fractional flow reserve (FFR) was calculated by ratio of Pd to Pa during maximal hyperemic
      status. Coronary flow reserve (CFR) was derived from dividing the resting Tmn by hyperemic
      Tmn.

      Continuous variables were presented as mean ± standard deviation (SD) and categorical
      variables as the number of patients (percentages). The one way analysis of variance (ANOVA)
      was used for comparing continuous variables. Additionally, post-hoc analysis was performed
      for evaluating to be significant by ANOVA. The Pearson's chi-square test or Fisher's exact
      test was used for analyzing categorical variables. Linear regression analysis was performed
      for investigating the association between NLR and variables using clinical, laboratory,
      echocardiographic, and angiographic data. A p value &lt;0.05 was regarded statistically
      significant. All statistical analyses were carried out with SPSS version 19.0 (SPSS inc.,
      Chicago, Illinois, USA).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Index of Microcirculatory Resistance</measure>
    <time_frame>3 months</time_frame>
    <description>IMR in low NLR group : 21.94 ± 12.87 IMR in intermediate NLR group : 23.22 ± 12.73 IMR in high NLR group : 32.95 ± 20.60</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">123</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Death</condition>
  <arm_group>
    <arm_group_label>Low NLR group</arm_group_label>
    <description>Neutrophil-to-Lymphocyte (NLR) Ratio &lt; 1.78</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermediate NLR group</arm_group_label>
    <description>1.78 &lt; Neutrophil-to-Lymphocyte (NLR) Ratio &lt; 3.90</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High NLR group</arm_group_label>
    <description>Neutrophil-to-Lymphocyte (NLR) Ratio &gt; 3.90</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 123 consecutive STEMI patients who underwent successful primary PCI and coronary
        physiologic study immediately after PCI were retrospectively enrolled in the study. All
        patients underwent index PCI between May 2009 and October 2014 at INHA university hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEMI patients who undergone primary PCI

        Exclusion Criteria:

          -  unprotected left main coronary artery disease

          -  stent thrombosis presentation

          -  a history of coronary artery bypass graft surgery

          -  prior intravenous thrombolytic therapy before PCI

          -  high degree atrioventricular block

          -  remained cardiogenic shock after complete PCI

          -  contraindication for use of adenosine

          -  post-PCI thrombolysis in myocardial infarction (TIMI) flow grade 0 or 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <results_first_submitted>July 9, 2016</results_first_submitted>
  <results_first_submitted_qc>July 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2016</results_first_posted>
  <last_update_submitted>July 9, 2016</last_update_submitted>
  <last_update_submitted_qc>July 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>If it is feasible to upload the individual data, the investigator would consider it positively.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low NLR Group</title>
          <description>Neutrophil-to-Lymphocyte (NLR) Ratio &lt; 1.78</description>
        </group>
        <group group_id="P2">
          <title>Intermediate NLR Group</title>
          <description>1.78 &lt; Neutrophil-to-Lymphocyte (NLR) Ratio &lt; 3.90</description>
        </group>
        <group group_id="P3">
          <title>High NLR Group</title>
          <description>Neutrophil-to-Lymphocyte (NLR) Ratio &gt; 3.90</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low NLR Group</title>
          <description>Neutrophil-to-Lymphocyte (NLR) Ratio &lt; 1.78</description>
        </group>
        <group group_id="B2">
          <title>Intermediate NLR Group</title>
          <description>1.78 &lt; Neutrophil-to-Lymphocyte (NLR) Ratio &lt; 3.90</description>
        </group>
        <group group_id="B3">
          <title>High NLR Group</title>
          <description>Neutrophil-to-Lymphocyte (NLR) Ratio &gt; 3.90</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="123"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>YEARS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="10"/>
                    <measurement group_id="B2" value="55" spread="11"/>
                    <measurement group_id="B3" value="58" spread="12"/>
                    <measurement group_id="B4" value="57" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Incheon Province in the Western part of South Korea</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Index of Microcirculatory Resistance</title>
        <description>IMR in low NLR group : 21.94 ± 12.87 IMR in intermediate NLR group : 23.22 ± 12.73 IMR in high NLR group : 32.95 ± 20.60</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low NLR Group</title>
            <description>Neutrophil-to-Lymphocyte (NLR) Ratio &lt; 1.78 IMR 21.94 ± 12.87</description>
          </group>
          <group group_id="O2">
            <title>Intermediate NLR Group</title>
            <description>1.78 &lt; Neutrophil-to-Lymphocyte (NLR) Ratio &lt; 3.90 IMR 23.22 ± 12.73</description>
          </group>
          <group group_id="O3">
            <title>High NLR Group</title>
            <description>Neutrophil-to-Lymphocyte (NLR) Ratio &gt; 3.90 IMR 32.95 ± 20.60</description>
          </group>
        </group_list>
        <measure>
          <title>Index of Microcirculatory Resistance</title>
          <description>IMR in low NLR group : 21.94 ± 12.87 IMR in intermediate NLR group : 23.22 ± 12.73 IMR in high NLR group : 32.95 ± 20.60</description>
          <units>IMR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.94" spread="12.87"/>
                    <measurement group_id="O2" value="23.22" spread="12.73"/>
                    <measurement group_id="O3" value="32.95" spread="20.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Low NLR Group</title>
          <description>Neutrophil-to-Lymphocyte (NLR) Ratio &lt; 1.78</description>
        </group>
        <group group_id="E2">
          <title>Intermediate NLR Group</title>
          <description>1.78 &lt; Neutrophil-to-Lymphocyte (NLR) Ratio &lt; 3.90</description>
        </group>
        <group group_id="E3">
          <title>High NLR Group</title>
          <description>Neutrophil-to-Lymphocyte (NLR) Ratio &gt; 3.90</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sung Woo Kwon</name_or_title>
      <organization>Inha University Hospital</organization>
      <phone>821031133363</phone>
      <email>kwonswdr@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

